Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

14.71 +0.06 (+0.41%)
Official Closing Price Updated: 7:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Cathie Wood Loads Up $42M In DraftKings As Shares Drop On Short-Seller Report
Cathie Wood-led Ark Investment Management on Tuesday snapped up 870,299 shares, estimated to be worth about $42.2 million, in DraftKings Inc (NASDAQ: DKNG) on the day shares of... 
Via Benzinga
Continued Uncertainty
Fear of another Fukushima yesterday late in the market day led to a rush out of energy-related shares, which included many without any nuclear risk at all. 
Via Talk Markets
Our Planet Commitment
SOURCE: Takeda 
Via 3BL Media
Dreary Day
Another dreary day and a renewed boost for cryptocurrency - and away from the classic inflation hedge, gold. 
Via Talk Markets
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs
Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves. The biggest biotech news of the week came in the form of approval... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs
Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves. The biggest biotech news of the week came in... 
Via Benzinga
Exposures Product Safety
Unheeding Markets
Today oil prices rose over $70. 
Via Talk Markets
Vertex Pharma Stumbles In Rare-Disease Effort, Buoying Rival Arrowhead Pharma
Vertex Pharmaceuticals scrapped development of a rare-disease treatment Thursday that appeared unlikely to benefit patients, and VRTX stock plunged. 
Via Investor's Business Daily
Blueprint for Access to Innovative Healthcare Episode 1: Awareness and Prevention
SOURCE: Takeda 
Via 3BL Media
Wednesday News And Catch-Up
Today the US market resumed its attempt to hit a new record for the S&P 500 and Nasdaq, but not the DJIA. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Global Diversity, Equity, and Inclusion Week at Takeda
SOURCE: Takeda 
Via 3BL Media
Phase 3 Clinical Trial Subgroup Analysis Across Solid Organ Transplant (SOT) Types Supports Efficacy of Maribavir Over Conventional Therapies in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)
From Takeda Pharmaceutical Company Limited
Via Business Wire
How Significant Are Moderna's Asian Regulatory Wins?
The biotech is poised to profit in both Japan and South Korea. 
Via The Motley Fool
Exposures COVID-19
A Better Switch
Today the US market decided to rise because President Biden is pondering not linking his infrastructure project to a corporate tax increase. 
Via Talk Markets
Fan Hit
The 10-yr US treasury yield rose to 1.6% again. Later in the day, a rally was attempted, mostly for the meme shares. 
Via Talk Markets
Wonder Products
Meme is alive and well. 
Via Talk Markets
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive... 
Via Benzinga
Exposures Product Safety
New New Deal Worries
Nio is up 1.4% today on another round of Meme buying. 
Via Talk Markets
Good Times For Gold
Gold is rising some more, in part as an alternative to crypto. 
Via Talk Markets
Sterling At Five-Year High
Today markets are mixed because of currency factors, with sterling bullishness against the dollar and the euro. 
Via Talk Markets
Takeda's Dengue Vaccine Effective In Reducing Hospitalization Regardless Of Prior Infection
Takeda Pharmaceutical Co Ltd (NYSE: TAK) unveiled long-term data for its dengue vaccine candidate (TAK-003), showing the shot’s efficacy waned over time but... 
Via Benzinga
Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
From Takeda Pharmaceutical Company Limited
Via Business Wire
Worldwide Upbeat
The US crackdown on cryptocurrencies continues with the Fed today indicating that an official crypto-currency is going to be created for the USA. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Takeda's Maribavir US Application For Post-Transplant CMV Infection Under Review
The FDA has accepted for review Takeda Pharmaceutical Co Ltd's (NYSE TAK) marketing application for maribavir for cytomegalovirus (CMV) Infection. The... 
Via Benzinga
Exposures Product Safety
Moderna's COVID-19 Vaccine Scores Emergency Use Nod In Japan
Moderna Inc (NASDAQ: MRNA) has received emergency use approval for its mRNA COVID-19 vaccine in Japan. Takeda Pharmaceutical Co Ltd (NYSE: TAK),... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 20) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Is BioCryst a Good Stock to Buy Now?
This commercial-stage drugmaker trades for less than many of its clinical-stage peers. 
Via The Motley Fool
Exposures Product Safety
U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treatment
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan
From Takeda Pharmaceutical Company Limited
Via Business Wire
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.